what this node claims
AlphaFold metrics / GLP1R
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
53%
low debt pressure
21%
82%structurestrong
pLDDT 81.51
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- confident
- confidence pct
- 81.51
- coverage context
- missing or not linked
- interpretation
- usable fold context with explicit model-confidence limits
- pae context
- missing or not linked
- plddt avg
- 81.51
- sequence length
- 0
AlphaFold metrics visual
Confident backbone model
463 residues / min 27.03 / max 98.25 / source alphafold db
Very high
47.1%
218 residues / >=90
Confident
35.6%
165 residues / 70-89
Low
5.8%
27 residues / 50-69
Very low
11.4%
53 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 463 of 463 residues.
- residues 432-463 / mean 43.36
- residues 1-30 / mean 39.91
- residues 130-137 / mean 55.76
- residues 370-376 / mean 59.89
proof debt register
21%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.